Free Trial

Lantheus (LNTH) Competitors

Lantheus logo
$78.27 -2.57 (-3.18%)
Closing price 03:59 PM Eastern
Extended Trading
$80.83 +2.56 (+3.27%)
As of 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LNTH vs. TEVA, SMMT, GMAB, ITCI, VTRS, MRNA, RDY, PCVX, SRPT, and QGEN

Should you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.

Lantheus vs.

Lantheus (NASDAQ:LNTH) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, community ranking, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Lantheus has a net margin of 28.57% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Lantheus' return on equity of 44.29% beat Teva Pharmaceutical Industries' return on equity.

Company Net Margins Return on Equity Return on Assets
Lantheus28.57% 44.29% 23.52%
Teva Pharmaceutical Industries -9.91%42.46%6.65%

Lantheus has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lantheus$1.30B4.22$326.66M$6.0113.09
Teva Pharmaceutical Industries$16.54B1.14-$1.64B-$1.45-11.50

Lantheus presently has a consensus price target of $131.86, indicating a potential upside of 67.58%. Teva Pharmaceutical Industries has a consensus price target of $23.57, indicating a potential upside of 41.35%. Given Lantheus' stronger consensus rating and higher possible upside, research analysts plainly believe Lantheus is more favorable than Teva Pharmaceutical Industries.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantheus
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86

Teva Pharmaceutical Industries received 991 more outperform votes than Lantheus when rated by MarketBeat users. Likewise, 67.87% of users gave Teva Pharmaceutical Industries an outperform vote while only 65.89% of users gave Lantheus an outperform vote.

CompanyUnderperformOutperform
LantheusOutperform Votes
340
65.89%
Underperform Votes
176
34.11%
Teva Pharmaceutical IndustriesOutperform Votes
1331
67.87%
Underperform Votes
630
32.13%

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 1.5% of Lantheus shares are owned by company insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Teva Pharmaceutical Industries had 9 more articles in the media than Lantheus. MarketBeat recorded 21 mentions for Teva Pharmaceutical Industries and 12 mentions for Lantheus. Lantheus' average media sentiment score of 0.98 beat Teva Pharmaceutical Industries' score of 0.88 indicating that Lantheus is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lantheus
7 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Teva Pharmaceutical Industries
12 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Lantheus has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.

Summary

Lantheus beats Teva Pharmaceutical Industries on 13 of the 18 factors compared between the two stocks.

Get Lantheus News Delivered to You Automatically

Sign up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LNTH vs. The Competition

MetricLantheusDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$5.47B$2.30B$5.82B$9.06B
Dividend YieldN/A0.75%4.78%3.85%
P/E Ratio13.095.0926.1619.03
Price / Sales4.2290.93455.9477.31
Price / Cash12.0715.7944.0437.47
Price / Book6.613.337.704.73
Net Income$326.66M-$65.73M$3.18B$245.69M
7 Day Performance-1.57%-2.12%-1.02%-1.33%
1 Month Performance-16.34%-7.47%1.10%-1.00%
1 Year Performance38.75%-14.50%18.06%15.52%

Lantheus Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LNTH
Lantheus
4.6124 of 5 stars
$78.27
-3.2%
$131.86
+68.5%
+42.3%$5.44B$1.30B13.02700Analyst Revision
TEVA
Teva Pharmaceutical Industries
2.9342 of 5 stars
$16.24
-2.4%
$23.57
+45.2%
+30.1%$18.39B$16.54B-11.2037,851
SMMT
Summit Therapeutics
2.3161 of 5 stars
$21.37
-2.1%
$33.57
+57.1%
+516.6%$15.76B$700,000.00-76.32110Gap Up
GMAB
Genmab A/S
4.6083 of 5 stars
$21.30
+1.8%
$42.17
+98.0%
-22.5%$14.10B$2.39B20.682,204
ITCI
Intra-Cellular Therapies
3.9604 of 5 stars
$127.82
-0.2%
$103.62
-18.9%
+74.4%$13.59B$464.37M-146.92560Earnings Report
Analyst Forecast
News Coverage
VTRS
Viatris
2.3367 of 5 stars
$10.80
flat
$13.67
+26.5%
-16.5%$12.89B$15.43B-14.5938,000News Coverage
MRNA
Moderna
4.7566 of 5 stars
$32.99
+3.4%
$66.89
+102.8%
-61.2%$12.70B$6.85B-5.675,600Analyst Downgrade
Options Volume
High Trading Volume
RDY
Dr. Reddy's Laboratories
2.8963 of 5 stars
$13.60
-2.8%
$17.00
+25.0%
-11.7%$11.35B$311.31B21.6527,048Gap Down
PCVX
Vaxcyte
2.6035 of 5 stars
$84.00
+0.2%
$127.71
+52.0%
+11.3%$10.47BN/A-18.26160Insider Trade
Positive News
SRPT
Sarepta Therapeutics
4.5135 of 5 stars
$107.95
-1.4%
$176.77
+63.8%
-20.4%$10.31B$1.24B86.361,314Upcoming Earnings
QGEN
Qiagen
4.4462 of 5 stars
$39.85
-0.5%
$48.78
+22.4%
-7.3%$8.84B$1.98B110.975,967Analyst Downgrade

Related Companies and Tools


This page (NASDAQ:LNTH) was last updated on 2/21/2025 by MarketBeat.com Staff
From Our Partners